Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings Inc (INFU) delivers essential medical equipment and outpatient care services across North America, specializing in infusion therapy solutions for oncology, pain management, and chronic care. This page provides investors and healthcare professionals with timely updates on the company's operational milestones and strategic initiatives.
Access consolidated INFU news including earnings announcements, regulatory filings, and partnership developments. Our repository features press releases related to medical device innovations, service expansions, and leadership updates – all critical for assessing the company's position in the durable medical equipment sector.
Key content categories include quarterly financial results, biomedical service enhancements, and coverage of INFU's dual-platform strategy balancing patient care with device lifecycle management. Bookmark this page to monitor INFU's progress in bridging clinical and home-based healthcare delivery.
InfuSystem Holdings reported a strong performance for Q1 2021, with net revenues of $24.5 million, a 14% increase year-over-year. The company achieved a net income of $0.7 million, up $1.1 million from the prior year, alongside an Adjusted EBITDA of $6.2 million, marking a 51% growth. The Adjusted EBITDA margin was 25.2%. InfuSystem reaffirmed its 2021 full-year guidance, anticipating revenues between $107 million and $110 million, with a projected Adjusted EBITDA margin of 27%.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its first quarter 2021 financial results on May 6, 2021, before the market opens. The Company provides outpatient care for durable medical equipment manufacturers and health care providers. A conference call for investors is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results. Investors can participate via phone or a live webcast, with a replay available for 90 days after the call.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the acquisition of assets from OB Healthcare Corporation, a Texas-based biomedical services firm. This strategic move enhances InfuSystem's Durable Medical Equipment Services (DME) platform, following a recent acquisition of FilAMed. The combination of OB Healthcare's on-site service capabilities and FilAMed's remote repair expertise aims to expand InfuSystem's market opportunities in acute care. CEO Richard DiIorio emphasized the synergy between both companies, which is expected to improve service offerings for their healthcare clients.
InfuSystem Holdings (NYSE American: INFU) will present at Sidoti’s Spring 2021 Virtual Conference on March 25, 2021, at 9:15 a.m. ET. CEO Rich DiIorio and CFO Barry Steele will discuss the company's role as a leading healthcare service provider facilitating outpatient care for durable medical equipment. Their services include Integrated Therapy Services and Durable Medical Equipment Services. Management will also hold one-on-one meetings with investors on March 24-25. A recorded webcast will be available afterward on InfuSystem’s website.
InfuSystem Holdings reported a remarkable financial performance for the full year 2020, reflecting a 20% increase in net revenues, reaching $97.4 million, and a 15.9 million surge in net income, totaling $17.3 million. Adjusted EBITDA climbed 44% to $26.2 million. For 2021, the company reaffirms its guidance with projected net revenues of $107 million - $110 million and adjusted EBITDA of $29 million - $30 million. Notably, the fourth quarter saw a 14% revenue increase, driven by significant growth in oncology and DME services.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its fourth quarter and full year 2020 financial results on March 17, 2021, before market opening. The company provides outpatient care services for durable medical equipment. Following the results announcement, a conference call will be held at 9:00 a.m. Eastern Time to discuss the financials. Investors can participate by calling (833) 366-1127 or through a live webcast on the company’s website. A replay will be available for 90 days.
InfuSystem Holdings announces the promotion of Carrie Lachance to President, adding to her current role as Chief Operating Officer. CEO Richard DiIorio praised her leadership in patient and customer care. This leadership change aims to strengthen the company’s growth strategy and enhance its two operational platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Lachance, with over 20 years of healthcare experience, focuses on scaling new therapies and products.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced a new $75 million revolving credit facility with JPMorgan Chase Bank, replacing a $49 million facility. Effective February 5, 2021, this facility enhances liquidity and financial flexibility, allowing the company to capitalize on growth opportunities in Integrated Therapy Services and Durable Medical Equipment Services. With this facility, InfuSystem's liquidity increases to over $45 million from approximately $20 million previously. The facility features a five-year term and an interest rate tied to the company's Total Leverage Ratio.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the acquisition of FilAMed, a biomedical services company based in Bakersfield, CA. Although the terms of the transaction were not disclosed, CEO Richard DiIorio emphasized the strategic importance of this acquisition in expanding InfuSystem's capabilities within its Durable Medical Equipment Services (DME) platform. The acquisition aims to enhance service offerings such as compression devices and patient monitors, while providing a broader range of services and facilitating entry into the acute care market.
InfuSystem Holdings, Inc. (NYSE: INFU) has announced its financial guidance for 2021, projecting net revenues of $107 million to $110 million, Adjusted EBITDA of $29 million to $30 million, and operating cash flow of $21 million to $23 million. Management anticipates strong growth driven by its Integrated Therapy Services (ITS) Segment, particularly in Pain Management and Negative Pressure Wound Therapy. Despite expecting tailwinds from COVID-19, they remain cautious about potential impacts on operations.
FAQ
What is the current stock price of Infusystem Hld (INFU)?
What is the market cap of Infusystem Hld (INFU)?
